Additionally, combining lactylation inhibitors with anti-PD-1/PD-L1 checkpoint blockade could enhance immunotherapy efficacy, particularly in prostate cancer patients who exhibit resistance to current immune checkpoint inhibitors. Here, CD274 is linked to prostate cancer.